The Annexure

News to 16 October 2026 ·

Desk›Healthcare› Cipla Ltd

Cipla Ltd

BSE 500087 · NSE CIPLA · ISIN INE059A01026 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹1,419.90

+0.82%

BSE close, 28 August 2026

Market cap

₹114,707.07 cr

80.8 cr shares · Large cap

Free float

₹80,522.18 cr

as published

P/E · P/B

37.3× · 3.94×

EPS ₹38.05 · BV ₹360.38

FY25-26 rev / PAT

18,979.95 / 3,515.18

₹ cr, as filed

Filings, window

21

6 selected · 29%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹1,165.55 52-WK HIGH ₹1,672.20 ₹1,419.90 50% of range
Against 52-week high-15.1%
Against 52-week low+21.8%
Day change+0.82%
Size bandLarge cap
Index membershipNIFTY 50, NIFTY 500

Valuation as published by BSE

Earnings per share₹38.05
Price / earnings37.32×
Price / book3.94×
Book value — derived, price ÷ P/B₹360.38
Return on equity10.55%
Operating margin26.17%
Net margin16.98%

Consistency check

P/B ÷ P/E, which must equal ROE
10.56%
ROE as published
10.55%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 5,077.68 862.16 10.67 26.17% 16.98%
Mar-26 · Q 4,209.98 384.64 4.76 17.75% 9.14%
FY25-26 18,979.95 3,515.18 43.52 28.00% 18.52%

Quarter on quarter

Revenue, quarter on quarter
+20.6%
Net profit, quarter on quarter
+124.1%
Operating margin, quarter on quarter
+842 bps

Disclosure profile 21 filings in the window

0 median 17.0 p75 · 24 sector max 59 21 64th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 24 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Press Release2
Change in Management1
Concall Transcript1
Restructuring1
Scheme of Arrangement1
Selected sub-total6
Procedural
General7
ESOP Allotment3
Analyst / Investor Meet2
Board Meeting1
Compliance Certificate1
Newspaper Publication1
Procedural sub-total15
Total21

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 98 trading days

21 filings · 6 selected · busiest 2026-07-27 and 2026-08-27

Filing rhythm · the twelve most recent

2026-08-272026-10-15

SelectedProcedural

Filings

21 in the window · 30 earlier on record

  1. 15 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 13 October 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Please find enclosed intimation for Earnings Conference Call.

    Company Update / Analyst / Investor Meet View filing →

  3. 28 September 2026 ·

    Board Meeting

    Board Meeting Intimation for The Quarter And Half Year Ended 30Th September, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Cipla Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated ....

    Board Meeting / Board Meeting View filing →

  4. 24 September 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 24th September, 2026 has allotted 12,168 ....

    Company Update / Allotment of ESOP / ESPS View filing →

  5. 22 September 2026 ·

    Change in Management

    Change in Management

    Please find enclosed disclosure relating to the Change in SMP.

    Company Update / Change in Management View filing →

  6. 18 September 2026 ·

    General

    Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please find enclosed disclosure on ESG Rating.

    Company Update / General View filing →

  7. 3 September 2026 ·

    Press Release

    Press Release / Media Release

    Please find enclosed press release titled 'Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US'

    Company Update / Press Release / Media Release View filing →

  8. 3 September 2026 ·

    General

    Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August, 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company

    Please find enclosed disclosure

    Company Update / General View filing →

  9. 2 September 2026 ·

    Newspaper Publication

    Newspaper Publication

    Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares

    Company Update / Newspaper Publication View filing →

  10. 31 August 2026 ·

    Press Release

    Press Release / Media Release

    Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"

    Company Update / Press Release / Media Release View filing →

  11. 28 August 2026 ·

    General

    Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA

    Please find enclosed disclosure.

    Company Update / General View filing →

  12. 27 August 2026 ·

    Restructuring

    Restructuring

    Please find enclosed disclosure.

    Company Update / Restructuring View filing →

  13. 27 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / ....

    Company Update / Analyst / Investor Meet View filing →

  14. 26 August 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    In terms of regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Admisnistrative Committee of the Company on 26th August, 2026 has allotted 5,281 fully ....

    Company Update / Allotment of ESOP / ESPS View filing →

  15. 25 August 2026 ·

    General

    USFDA Inspection At Company'S Manufacturing Facility In Pithampur, India

    Please find enclosed disclosure

    Company Update / General View filing →

  16. 19 August 2026 ·

    Scheme of Arrangement

    Scheme of Arrangement

    Cipla has informed the exchange about receipt of order from Hon'ble NCLT, Mumbai Bench

    Company Update / Scheme of Arrangement View filing →

  17. 11 August 2026 ·

    General

    Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please find attached disclosure on ESG Ratings.

    Company Update / General View filing →

  18. 4 August 2026 ·

    General

    Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA

    Please find enclosed intimation.

    Company Update / General View filing →

  19. 31 July 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015, we hereby notify that the Operations and Administrative Committee ....

    Company Update / Allotment of ESOP / ESPS View filing →

  20. 27 July 2026 ·

    General

    Cipla Receives U.S. FDA Approval For Generic Advair Diskus®

    Please find enclosed disclosure

    Company Update / General View filing →

  21. 27 July 2026 ·

    Concall Transcript

    Earnings Call Transcript

    Please find enclosed Earnings Call Transcript - Q1FY27

    Company Update / Earnings Call Transcript View filing →

RSS feed for Cipla Ltd · the 50 most recent filings